Navigation Links
Johnson & Johnson Reports 2014 Second-Quarter Results:
Date:7/15/2014

pan">7,3017,333(0.4)1.5(1.9)PharmaceuticalU.S.4,6133,37736.636.6-8,3536,84822.022.0-International3,8963,6486.86.9(0.1)7,6546,94510.211.6(1.4)8,5097,02521.121.10.016,00713,79316.116.8(0.7)Med Devices & DiagnosticsU.S.3,1993,243(1.4)(1.4)-6,3546,449(1.5)(1.5)-International4,0433,9512.32.6(0.3)7,9487,807'/>"/>
SOURCE Johnson & Johnson
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation
2. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
3. Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
4. Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
5. Johnson & Johnson Settlement Resolves Metal Hip Lawsuits But Weak Oversight Of Medical Device Industry Leaves Hundreds of Thousands of Patients Vulnerable
6. KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
7. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
8. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
9. Johnson & Johnson Reports 2013 Second-Quarter Results:
10. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
11. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  The report on breast cancer therapeutics: pipeline ... drugs on the basis of the molecules which are ... inner lining of milk ducts or lobules responsible for ... tumor that can spread to other cells present in ... lobules is referred as lobular carcinoma, while the other ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... an X-linked disease, which generally affects the male ... and weakness. The disease is caused due to ... the lack of production of dystrophin (a protein ... The lack of dystrophin weakens muscle function, causes ...
(Date:9/2/2015)... 2015 About Chronic Lymphocytic Leukemia ... by increased production of lymphocytes. It has been observed ... can spread to other parts of the body. This ... the slow buildup of the cancerous cells. During the ... spleen, liver, and lymph nodes. The course of the ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
...  24, 2011 Sanofi (EURONEXT: SAN and NYSE: ...  of its once-daily GLP-1 receptor agonist Lyxumia® (lixisenatide) that ... demonstrates positive results in type 2 diabetes patients not ... These data are being presented or published at the ...
... 2011 Daniels Sharpsmart Inc., the world,s largest provider ... Bronx medical waste facility from Stericycle making Daniels the ... (Photo: http://photos.prnewswire.com/prnh/20110624/DC25808 ) ... in the United States, significantly expands Daniels, capabilities throughout ...
Cached Medicine Technology:Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 2Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 3Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 4Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 5Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 6Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 7Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 8Daniels Jumps to No. 2 in Medical Waste Disposal Industry 2
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, ... of her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” ... Hartley’s guide to overcoming life’s obstacles by taking full responsibility for one’s life ...
(Date:9/3/2015)... ... September 03, 2015 , ... For the second year ... Inc. 5000 list of fastest-growing private companies in America. President and Editor-in-Chief ... nation's companies have demonstrated such remarkably consistent high growth, particularly in the difficult ...
(Date:9/3/2015)... ... 03, 2015 , ... According to an Oncology Nurse Advisor article ... patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for relapses ... HPV infections, which have a high rate of success in treatment and elimination of ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... 31, 2015: DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, ... by current board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... responsibility concierges; simplifying responsibilities which can impact the delicate life balance between work ... situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency ...
Breaking Medicine News(10 mins):Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3
... , VIENNA, Va., Sept. 2 ... developer of vaccines for the prevention and treatment of infectious diseases ... K convertible notes (the "Notes"). The Notes, which had an ... and were convertible into common stock. , , ...
... 2 Shari Tetrick says the scooter she rented for her husband, ... fine at home, but on a large ship and shore excursions, I ... I wasn,t going to let anything ruin this cruise." , , ... her father. "The Explorer of the Seas is HUGE and dad wouldn,t ...
... , , ... /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, ... developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused ... and Chief Executive Officer, will present a corporate overview at the ...
... children, study found , WEDNESDAY, Sept. 2 (HealthDay News) -- ... but a new study concludes that weight-loss surgery can break ... surgery before becoming pregnant had children who were less likely ... before the weight-loss surgery. , The study findings show ...
... Sept. 2 "Everyone is looking for ways to protect ... about my personal encounter with the virus. About three months ... where he describes his discovery of the relationship between chronic ... started taking Gene-Eden, a broad range antiviral supplement, to reduce ...
... WASHINGTON, Sept. 2 Danaher Corporation (NYSE: ... agreement with MDS Inc. (TSX: MDS; NYSE: MDZ ... includes a 50% ownership position in Applied Biosystems/MDS Sciex joint ... ownership position in the former Molecular Devices Corporation, a bioresearch ...
Cached Medicine News:Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 2Health News:Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Weight-Loss Surgery Breaks Families' 'Obesity Cycle' 2Health News:How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement' 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4
For the screening and detection by indirect immunofluorescence (IF) of primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
... assay that quantifies the likelihood of breast ... early stage breast cancer. In addition to ... assesses the benefit from certain types of ... paraffin-embedded tumor tissue analyzes the expression ...
... The Her-2/neu protein is a 185 ... activity. Approximately 20-30% cases of breast cancer ... in tumor cells. Since the introduction of ... cancer, the clinical testing of Her-2/neu in ...
Medicine Products: